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Abstract
Inducible degrader of the low density lipoprotein receptor (IDOL), is an E3 ubiquitin ligase
that negatively modulates low density lipoprotein receptor (LDL-R) expression. Genome-
wide association studies (GWAS) indicated that genetic variants in IDOL gene contributes to
variation in LDL-C plasma levels and the detailed analysis of a specific locus resulted in the
identification of the functional common single nucleotide polymorphism (SNP) rs9370867 (c.
G1025A, p.N342S) associates with increased LDL-R degradation and increased LDL-C lev-
els. These findings, however, were not confirmed in two other independent cohorts and no
data about the impact of this variant on atherosclerosis progression and cardiovascular risk
are available. Aim of this study was to investigate the association between a functional variant
in IDOL and atherosclerosis progression in an Italian general population. 1384 subjects en-
rolled in the PLIC study (Progression of Lesions in the Intima of Carotid) were genotyped by
Q-PCR allelic discrimination and the association with anthropometric parameters, plasma lip-
ids and the carotid intima media thickness (cIMT) and the impact on cardiovascular disease
(CVD) incidence were investigated. The N342S variant was not associated with changes of
the plasma lipid profile among GG, AG or AA carriers, including total cholesterol (249±21,
249±19 and 248±21 mg/dl respectively), LDL-C (158±25, 161±22 and 160±23 mg/dL), cIMT
(0.74±0.14, 0.75±0.17 and 0.77±0.15 mm) and CVD incidence. In agreement, the expression
of LDLR and the uptake of LDL was similar in macrophages derived fromGG and AA carriers.
Taken together our findings indicate that the N342S variant does not impact plasma lipid pro-
file and is not associated with atherosclerosis progression and CVD in the general population,
suggesting that other variants in the IDOL genemight be functionally linked with cholesterol
metabolism.
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Introduction
Elevated levels of circulating low density lipoprotein cholesterol (LDL-C) represent a key factor
for cardiovascular disease (CVD) risk [1]. Plasma LDL-C levels are mainly regulated by the
production and the clearance of apolipoprotein B (apoB) containing lipoproteins by the liver.
A central role in the hepatic LDL-C metabolism is played by the low density lipoprotein recep-
tor (LDLR) that mediates the uptake of LDL in the hepatocytes, thus promoting their clearance
[2]. LDLR gene mutations account for the majority of the cases of autosomal dominant hyper-
cholesterolemia (ADH 1), a genetic disease characterized by elevated LDL-C levels and prema-
ture CVD death [3]. The LDLR activity is controlled at the transcriptional level by the nuclear
translocation of the sterol regulatory element binding protein 2 (SREBP2) [4]. LDL-R expres-
sion is also controlled by the pro-protein convertase subtilisin-like kexin type 9 (PCSK9) which
binds the LDLR at the plasma membrane of the hepatocytes and induces its degradation in the
lysosomes [5]. Circulating PCSK9 is mainly produced by the liver and in analogy with the
LDLR is controlled by SREBP2 activity, thus making PCSK9 an interesting target for the devel-
opment of lipid lowering drugs [6]. In addition to PCSK9, the inducible degrader of the LDLR
(IDOL, also known as MYLIP) also controls the LDLR abundance by mediating the ubiquitina-
tion of the intracellular tail of the receptor and its lysosomal degradation [7]. In contrast to
PCSK9, IDOL expression is ubiquitous and regulated by the oxidized sterols sensitive nuclear
receptor liver X receptor (LXR) [8]. Hepatic overexpression of the IDOL gene in mice results in
hypercholesterolemia and atherosclerosis development [7,9]. In humans IDOL has been sug-
gested as a candidate gene involved in the modulation of lipoproteins metabolism by genome-
wide association studies (GWAS)[10–12]. Further investigation aimed at identifying the IDOL
genetic variants responsible for the association generated controversial results. In a Mexican
dyslipidemic population fine mapping of the IDOL gene identified the common rs9370867
SNP as the susceptibility variant associated with total cholesterol levels [13]. The rs9370867
SNP encodes the amino-acid substitution N342S, located in the FERM domain of the protein,
a critical region involved in the regulation of protein-protein interaction. The presence of a Ser-
ine residue (encoded by the G allele) reduces the ability of the IDOL protein to ubiquitinate the
LDLR, thus increasing plasma membrane LDLR expression and LDL clearance. This observa-
tion was not replicated in two Brazilian cohorts, characterized by mixed ethnicity, where the
same variant was not associated with LDL-C levels both the general population and in patients
with stable angina [14]. Finally, analysis of IDOL gene variants in the Dutch population
showed similar allelic frequencies of the rs9370867 SNP in two cohorts with extremely high
and low LDL-C levels [15], further questioning the functional relevance of this variant. In this
study we aimed at clarifying the contribution of the rs9370867 SNP in the IDOL gene to plasma
cholesterol levels and the association with a preclinical marker of atherosclerosis such as the
common carotid artery intima media thickness (cIMT). For this purpose we genotyped a co-
hort representative of the Italian general population enrolled in the PLIC study (Progression of
Lesions in the Intima of Carotid- Caucasian ethnicity)[16–18] and we investigated the associa-
tion of the rs9370867 SNP with the lipid profile, cIMT, and the incidence of cardiovascular dis-
ease (CVD) after a 10 years follow-up. We found no association of plasma lipid profile with
cIMT and CVD incidence. Moreover we observed similar LDL uptake capacity in macrophages
generated from peripheral blood mononuclear cells from IDOL rs9370867 GG or AA carriers.
Taken together our results indicate that other variants, if any, are likely to be responsible for
the relationship between plasma LDL-C levels and genetic variation in the IDOL gene evi-
denced by recent GWAS in Caucasian populations.
IDOL and Atherosclerosis
PLOS ONE | DOI:10.1371/journal.pone.0122414 April 30, 2015 2 / 12
Materials and Methods
Population sample
A cohort of 2141 subjects attending the Atherosclerosis Center in Bassini Hospital, Department
of Pharmacological and Biomolecular Sciences (University of Milan, Italy), were recruited for
the PLIC study. The PLIC study was approved by the Ethics Commitee of the University of
Study of Milan (approved on 06-02-2001 SEFAP protocollo n°0003/2001), all participants signed
a written informed consent. The investigation was performed in accordance with the principles
of the Declaration of Helsinki. This project is a study designed to investigate the presence and
progression of atherosclerotic lesions and intima media thickness (IMT) in the carotid artery of
a large local cohort in relation to the major cardiovascular disease risk factors. Exclusion criteria
were use of hypolipidemic drugs, presence of liver or kidney disease, thyroid dysfunction. 1384
subjects gave their signed consent to use their DNA for genetic studies addressing the cardiovas-
cular system. Biochemical and clinical variables were evaluated as previously described [19,20].
High resolution B-mode ultrasonography of carotid Intima-Media Thickness (c-IMT) with a lin-
ear ultrasound probe (4.0–13.0 MHz frequency, 14X48 mm footprint, 38 mm field of view) was
performed (Vivid S5 GE Healthcare1, Wauwatosa, WI, USA). The determination were per-
formed by a single sonographer, blinded to the subject’s identity (intra‐class correlation = 0.812,
n = 30). All the measurements were done off-line using the software provided by the instrument
[21]. The protocol involved the common carotid artery (CCA) (30 mm proximal to the carotid
bulb), the carotid bulb and internal carotid artery (ICA) at both sides. The intima-media thick-
ness (IMT) was assessed at the far wall as the distance between the interface of the lumen and in-
tima, and the interface between the media and adventitia in a standardized number of points
[21,22]. The maximal IMT was recorded and averaged for the left and right sides of the CCA
(30 mm proximal to the carotid bulb), the carotid bulb, the ICA. Presence of extra-cardiac ath-
erosclerotic vascular involvement was determined with presence of focal plaques (> 1.3 mm in
longitudinal resolution, lateral or medial angle) and/or diffusive mean IMT> 1.3 mm (in longi-
tudinal resolution, lateral or medial angle)[23].
The protocol involved the determination of the Left Ventricular Mass (LVM) assessment.
The measurements were performed by two dimensional guided M-mode echocardiography
from the parasternal window using an M-mode color-Doppler (Vivid S5 GE Healthcare1,
Wauwatosa, WI, USA) (1.4–4.0 MHz frequency, 19.3X27.6 mm footprint wide-band phased
array transducer). Left Ventricular Mass (LVM) was calculated with Devereux’s formula, ac-
cording to guidelines. The definition of cardiovascular events (CVEs) included coronary heart
disease (CHD), such as acute myocardial infarction (AMI), acute coronary syndromes, acute
and chronic heart failure (New York Heart Association class II and III); peripheral artery dis-
ease (PAD) and cerebrovascular events, such as stroke, transient cerebral ischemic attack in the
previous 6 months, and other vascular complications (including diabetic foot ulcers). In addi-
tion having undergone major surgery was included in this definition (i.e.: carotid thrombo-
arterectomy, percutaneous coronary angioplasty, arterial angioplasty or arterial by-pass of the
lower limbs, coronary by-pass and amputations). Cardiovascular risk was defined in accor-
dance to the Progetto Cuore individual risk score, for the Italian population as described [23].
Genotyping
Genomic DNA was extracted from buffy coat samples using the Flexigene DNA kit (Qiagen,
Milan, Italy) according to the manufacturer’s instructions. Genotyping for the rs9370867
IDOL SNP (c.G1025A, p.N342S) was performed on 5 μL (10–200 ng of DNA), using a TaqMan
IDOL and Atherosclerosis
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allelic discrimination test. Taqman SNP Genotyping assay Code N. C_2461770_10 (Thermo
Fisher Scientific, Applied Biosystems, Waltham, MA).
Peripheral blood mononuclear cells and macrophages cell culture
Peripheral blood mononuclear cells (PBMCs) were collected from 10 patients previously en-
rolled in the PLIC study (n = 5 carriers of the AA genotype and n = 5 carriers of the GG geno-
type, the two groups were matched for sex and age) as reported [24]. Briefly blood was diluted
1: 3 in Phosphate Buffered Saline (PBS) (15 mL) then layered onto 4 mL of Ficoll Hipaque
(Amersham) and centrifuged at 1500 rpm for 35 min. PBMCs were removed from the interface
and washed twice in PBS before being re-suspended in RPMI-1640 medium supplemented
with penicillin (50 U/ml), streptomycin (50 μg/ml), L-glutamine (2 mM) and 10% serum AB.
PBMCs were counted and 2x106 cells were plated in 6 well plates and incubated for 2 hours in
a humidified atmosphere (37°C, 5% CO2). Non adherent cells were removed with four rinses of
PBS and attached monocytes cultured for 7 days to obtain monocyte-derived macrophages.
Gene expression analysis
Total RNA was extracted from monocytes-derived macrophages and 1 μg of RNA underwent
reverse transcription using the IScript cDNA Synthesis kit (BioRad, Milan, Italy) [24,25].
Three μL of cDNA were amplified by real-time quantitative PCR with 2X MAXIMA SYBR
Green/Fluorescein qPCR mastermix (Carlo Erba Reagents, Cornaredo, Italy)[26]. The specific-
ity of the Sybr green fluorescence was tested by plotting fluorescence as a function of tempera-
ture to generate a melting curve of the amplicon. Each sample was analyzed in duplicate using
the CFX Connect Real Time detection system (BioRad, Milan, Italy). The primers used are the
following: 18S: Fw 5’-CGCAGCTAGGAATAATGGAATAGG-3’, Rw5’- CATGGCCTCAGTT
CCGAAA-3’; LDLR: Fw 5’- GTGTCACAGCGGCGAATG -3’, Rw 5’- CGCACTCTTTGAT
GGGTTCA -3’. IDOL: Fw 5’- GATAACAGAGACGCACGCATTC -3’, Rw 5’- CCCTT
CAAGTCACGGCTATACTG -3’.
LDL preparation and macrophage LDL uptake assay
LDL (density 1.019–1.063 g/ml) were obtained from freshly isolated human plasma from
healthy volunteers by preparative ultracentrifugation in KBr gradient, dialyzed versus PBS con-
taining 0.01% EDTA and sterilized by filtration. Protein content was determined by the colori-
metric Lowry assay, using BSA as a standard. We then used a flow-cytometry assay to evaluate
LDL uptake by using fluorescently labelled LDL, a widely and robust assay currently used for
the investigation of LDLR function [27,28]. 1mg of LDL was labelled overnight at 4°C in 1 mL
PBS containing 0,5mg/mL of 3,30-dioctadecyloxacarbocyanine perchlorate (DiO) (stock solu-
tion 5mg/mL in dimethylformamide) (Sigma Aldrich, Milan, Italy). DiO-LDL were then isolat-
ed again by ultracentrifugation in KBr gradient and the excess of fluorescent probe and KBr
salt was removed by dialysis versus PBS containing 0.01% EDTA. LDL were sterilized by filtra-
tion and the protein content determined as previously described. Monocytes-derived macro-
phages were washed with PBS then incubated with 10μg/mL of DiO-LDL in RPMI without
serum
After 2 hours cells were washed three times with PBS, gently scraped off and collected in
tubes for flow cytometry analysis. Cells were immediately analyzed using a FACSCalibur flow
cytometer (BD Biosciences) and CellQuest software.
IDOL and Atherosclerosis
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Statistical analysis
Data were analyzed using IBM-SPSS 21.0 for Windows (Chicago, IL, USA). Results are re-
ported as mean ± SD, if not otherwise stated; Grubb’s test was performed to verify presence of
outliers data. Group differences among genotypes were determined by using one way Analysis
of Variances (ANOVA) test followed by LSD and Bonferroni post-hoc analyses; otherwise
Kruskal-Wallis test was then performed to compare not normally distributed variables across
the three genotypes. Then the Multivariable Analysis of Variances (MANOVA) was performed
to adjust the comparisons with other covariates, if significantly different among genotypes. Stu-
dent’s t-test for continuous normally-distributed variables (when appropriate) and χ2 analysis
for categorical variables were performed for the analysis of the alleles. Group differences with
P< 0.05 were deemed as statistically significant.
Results
General characteristics of subjects from the PLIC population according
to the rs9370867 SNP
No deviation from the Hardy-Weinberg equilibrium was observed for the rs9370867 (c.
G1025A) SNP. In the PLIC population analyzed (n = 1384) the allelic frequencies were 48.01%
and 51.99% for the G and A allele respectively, no significant differences in the genotypes dis-
tribution between men (n = 485) and women (n = 899) were observed (Table 1). No major dif-
ferences were found in the anthropometric and biochemical parameters, such as total
cholesterol (TC), LDL-C, high density lipoprotein cholesterol (HDL-C), triglycerides (TG) and
glycaemia among carriers of the different genotypes. (Table 2). Previous association of the
rs9370867 SNP with cholesterol metabolism were observed in a Mexican dyslipidemic popula-
tion, characterized by high levels of TC and TG. For this reason we stratified the PLIC popula-
tion according to TG and TC plasma levels and we repeated the analysis in two sub-groups
upper the 75th percentile of TC (mean value 271.2 ± 23.7 mg/dL) and TG (mean value
191 ± 71,1mg/dL). The results were similar compared to the whole population and showed no
significant impact of the rs9370867 (c.G1025A) SNP on the lipid profile, S1A and S1B Table
Impact of the rs9370867 SNP for IDOL on carotid atherosclerosis and
the prevalence of cardiovascular events
Although no association between the rs9370867 SNP and LDL-C or other lipid variables were
observed, this does not exclude the possibility that this functional SNP might affects other
pathways associated with cardiovascular disease. Therefore to further investigate the potential
role for the rs9370867 SNP, its association with left ventricular mass and intima media thick-
ness of carotid arteries (Fig 1A and Fig 1B) and the incidence of coronary heart disease,
Table 1. Genotypic [n(%)] and allelic frequencies (%) of the rs9370867 SNP in the PLIC population.
Genotype Allele
n GG GA AA G A
PLIC 1384 328(23.7%) 673(48.6%) 383(27.7%) 48.01% 51.99%
Men 485 127(26.2%) 230(47.4%) 128(26.4%) 49.9% 50.1%
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peripheral artery disease and cardiovascular events (CHD, PAD and CVE) was investigated
(Fig 2A to Fig 2C). The results show that the rs9370867 genotype is not associated with any of
the parameters investigated. Also when carriers of the A allele both in homozygosis and in het-
erozygosis were compared to carriers of the G allele, no differences in the odd ratio for the inci-
dence of CHD, PAD or CVE were observed. These data limit the impact of rs9370867 SNP for
IDOL on cardiovascular outcome.
LDLR expression and activity according to the rs9370867 SNP
The relevance of the rs9370867 IDOL SNP on LDL-R expression was further investigated in
macrophages generated from peripheral blood mononuclear cells from N342 or S342 IDOL
carriers. LDL-R expression and the capacity to internalize LDL particle, as a functional readout
of the LDL-R activity. LDL-R mRNA expression and IDOL mRNA expression were similar in
N342 and S342 macrophages (Fig 3A) and more importantly the genotype was not associated
with differences in LDLR function. N342 and S342 macrophages showed indeed the same lev-
els of LDL uptake, as assessed by flow cytometry after incubation of the cells with fluorescently
labelled LDL particle (Fig 3B and Fig 3C).
Discussion
GWAS study in European descent, showed that MYLIP (IDOL) genetic loci are associated with
plasma lipid levels [10–12]. The rs9370867 variant on the IDOL gene was initially proposed as
a gain of function variant associated with increased LDL-cholesterol levels [13]; however subse-
quent papers questioned the association of this variant with increased plasma total cholesterol
levels both in Brazilians [14] and in Caucasians [15].
For this reason, we investigated in a large cohort from the Italian general population the im-
pact of the same variant of the IDOL gene on plasma lipid parameters and on marker of pe-
ripheral atherosclerosis. In agreement with studies in Brazilian and Dutch cohorts [14,15], the
IDOL SNP was not associated with any relevant difference on plasma lipid profiles. Of note,
while in Europeans the rs9370867 SNP variant is in strong linkage disequilibrium with two up-
stream genome-wide significant GWAS variants rs2294261 [11], and rs2480 [12], this is not
true in the Mexican population [13]. This finding raises the possibility that other SNPs could
explain the relevance of the MYLIP locus in the control of plasma lipoprotein levels in Europe-
ans [11] as opposed to what observed in the Mexican population. However neither rs2294261
nor rs2480 exhibited a potential regulatory effect using cis-eQTL analysis [13], suggesting that
Table 2. Anthropometric and biochemical characteristics according to the rs9370867 SNP in subjects from the PLIC population.
GG AG AA P-value GG vs AA P-value GG vs GA P-value AA vs GA
Age 65.21 ± 9.97 64.36 ± 1.084 64.90 ± 9.88 0.735 0.342 0.515
Body mass index (Kg/m2) 26.8 ± 4.6 26.7 ± 4.3 27.0 ± 4.2 0.756 0.739 0.456
Total cholesterol (mg/dL) 209.9 ± 35.9 206.1 ± 34.6 204.7 ± 34.3 0.089 0.172 0.570
LDL-cholesterol (mg/dL) 125.2 ± 32.8 123.3 ± 31.9 122.6 ± 31.6 0.356 0.449 0.775
HDL-cholesterol (mg/dL) 64.60 ± 18 63.08 ± 16.18 62.64 ± 14.8 0.168 0.249 0.701
Triglycerides (mg/dL) 100.5 ± 42.4 98.91 ± 48.0 97.27 ± 45.6 0.391 0.646 0.634
Apolipoprotein A-I (mg/dL) 158.2 ± 23.4 156.4 ± 21.0 155.3 ± 20.7 0.133 0.311 0.455
Apolipoprotein B (mg/dL) 108.7 ± 22.1 105.6 ± 22.2 107.0 ± 22.2 0.389 0.078 0.380
SBP (mmHg) 128 ± 17 129 ± 18 128 ± 18 0.568 0.352 0.749
DBP (mmHg) 82.03 ± 9.4 82.37 ± 8.7 82.32 ± 8.8 0.983 0.228 0.195
Glucose (mg/dL) 95.38 ±15.89 94.97 ± 17.93 92.94±13.72 0.057 0.762 0.091
doi:10.1371/journal.pone.0122414.t002
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other studies are need to identify the actual casual variants for these GWAS signals. Further-
more the frequency of allele “A” and “G” alleles for rs9370867 variants of IDOL in our subjects
was similar to what reported in larger genome databases but differs from that reported by
Weissglas- Volkov et al in the Mexican dyslipidemic cohort [13]. While these aspects support
the importance of adjustment for ethnicity, when this was performed in the Brazilian cohort,
again no significant association of the N342S variant was observed [14].
In the attempt to investigate whether, despite the absence of a significant association to plas-
ma lipid levels, the rs9370867 variant on the IDOL gene impacts cardiovascular outcome, we
investigated its association with cardiac and vascular damage. Carriers of the different alleles
for the rs9370867 variant on the IDOL gene present a similar degree of cardiac and vascular
dysfunction and more importantly do not differ for the prevalence of either coronary heart dis-
ease, peripheral vascular disease or cardiovascular events. Our observations further support a
limited impact of this variant in Europeans and strongly support the need of validating the as-
sociation with cardiovascular outcome also in the Mexican cohort.
Fig 1. Heart left ventricular mass and carotid intimamedia thickness of the common carotid arteries
in the PLIC population according to the rs9370867 IDOL SNP. Panel A shows the mean ± SD for left
ventricular mass for GG, AG or AA carriers. Panel B shows the mean ± SD of carotid intima media thickness
of the common carotid arteries (right and left) for GG, AG or AA carriers.
doi:10.1371/journal.pone.0122414.g001
IDOL and Atherosclerosis
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Fig 2. Incidence of coronary heart disease (CHD), peripheral artery disease (PAD) and cardiovascular
events (CVE) in the PLIC population according to the rs9370867 SNP. Panels A, B and C shows the
incidence (%) of CHD, PAD and CVE for GG, AG or AA carriers of the rs9370867 IDOL SNP. Panel D shows
the risk CHD, PAD and CVE for the carriers of A allele of the rs9370867 vs carriers of the G allele. Odds
Ratios (OR, the 95% Confidence Interval (C.I.), adjusted for age, gender, lipid profile, systolic blood pressure,
glucose levels and therapies) are not statistically significant.
doi:10.1371/journal.pone.0122414.g002
IDOL and Atherosclerosis
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Based on the lack of association between the rs9370867 variant with plasma lipid variables,
metabolic determinants as well as markers of cardiac and vascular dysfunction, we decided to
investigate whether the N342S substitution affects IDOL function. Previous data, generated by
cotransfecting human embryonic kidney 293T cells (HEK293T) with plasmids for LDLR and
either N342 IDOL or S342 IDOL showed that the presence of N342 is associated with increased
LDL-R receptor degradation [13] pointing toward a functional effect for the rs9370867 variant.
This finding however was not confirmed in a different work, which was performed under the
same experimental conditions by overexpressing the LDL-R and N342S IDOL variant in
HEK293T cells [15]. To shed more light on this conflicting result and given that IDOL is widely
Fig 3. mRNA expression of LDL-R and IDOL and LDL uptake in macrophages from N342 and S342
macrophages. Panel A shows mRNA expression for LDL-receptor and for IDOL in macrophages obtained
from N342 and S342 carriers (n = 5 for both genotypes) cultured in complete RPMI medium The results,
normalized for the expression of an housekeeping gene (18S), data are shown as mean ± SEM. Next flow
cytometry was used to study the LDL uptake in macrophages obtained from N342 or S342 carriers. To
determine the LDL uptake, macrophages were incubated with fluorescently labelled LDL (DiO-LDL, 10 μg/
mL) for 2 hours at 37°C. Panel B shows representative images for flow cytometry in N342 and S342
macrophages, with the gating strategy of macrophages (inside panel) and the fluorescence intensity for Dio-
LDL while panel C shows the results from five N342 and five S342 patients (mean intensity fluorescence is
given, mean ± SEM is shown).
doi:10.1371/journal.pone.0122414.g003
IDOL and Atherosclerosis
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expressed [7], we decided to investigate directly in primary human cells the impact of the
rs9370867 variant and therefore isolated PBMCs and generated macrophages from N342 and
from S342 IDOL carriers.
IDOL mRNA expression was not different in N342 or S342 IDOL carriers and more impor-
tantly LDL-R functionality, measured as the cell ability to uptake fluorescent labelled LDL was
similar between N342 or S342 macrophages. These data obtained in primary cells further limit,
also at the molecular levels, the impact of the rs9370867 variant on the IDOL gene. Of note, pa-
tients with familial hypercholesterolaemia, when stratified according to the rs9370867 variant,
had similar baseline plasma lipid levels but presented a different magnitude of LDL-C reduc-
tion following statin therapy, suggesting that a pharmacogenetic effect for this IDOL SNP
could exist [29]. A similar finding was observed for another IDOL SNP (Rs6924995) in patients
treated with rosuvastatin [30]. In our cohort, NN342 carriers and SS342 carriers, when moved
on statin therapy, showed a similar magnitude of LDL-C reduction (data not shown).
Based on these observations, the possibility that, in vitro, sterol deprivation followed by
LXR stimulation could maximise the conditions to appreciate a difference, if any, on LDL up-
take in carriers of the different isoforms should be considered.
However, it is unlikely, that these conditions occur in the general population and the clinical
data point to a similar prevalence of cardiovascular disorders when stratifying for the rs9370867
variant on the IDOL gene.
In conclusion, although IDOL represents a key player in LDL-R biology and subsequent
risk of dyslipidemia and atherosclerosis, the functional and clinical impact of the N342S variant
is limited. The inclusion of this variant for improving genetic scores for hypercholesterolemia
or pharmacological approaches addressed at interfering with the region surrounding the aa
342 of the enzyme should be carefully reconsidered.
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